Hirokazu Miki

Dr. Hirokazu Miki


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MAMohannad Ashtar
Mohannad Ashtar
HTHirofumi Tenshin
Hirofumi Tenshin
JTJumpei Teramachi
Jumpei Teramachi
ABAriunzaya Bat-Erdene
Ariunzaya Bat-Erdene
MHMasahiro Hiasa
Masahiro Hiasa
MAMasahiro Abe
Masahiro Abe
Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. In the present study, we therefore explored the role of cancer-treatment-induced ROS in RANKL-mediated osteoclastogenesis and the suppressive effects of febuxostat on ROS generation and osteoclastogenesis. RANKL dose-dependently induced ROS production in RAW264.7 preosteoclastic cells; however, febuxostat inhibited the RANKL-induced ROS production and osteoclast (OC) formation. Interestingly, doxorubicin (Dox) further enhanced RANKL-induced osteoclastogenesis through upregulation of ROS production, which was mostly abolished by addition of febuxostat. Febuxostat also inhibited osteoclastogenesis enhanced in cocultures of bone marrow cells with MM cells. Importantly, febuxostat rather suppressed MM cell viability and did not compromise Dox’s anti-MM activity. In addition, febuxostat was able to alleviate pathological osteoclastic activity and bone loss in ovariectomized mice. Collectively, these results suggest that excessive ROS production by aberrant RANKL overexpression and/or anticancer treatment disadvantageously impacts bone, and that febuxostat can prevent the ROS-mediated osteoclastic bone damage.

18 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SOShuji Ozaki
Shuji Ozaki
THTakeshi Harada
Takeshi Harada
HYHikaru Yagi
Hikaru Yagi
ESEtsuko Sekimoto
Etsuko Sekimoto
HSHironobu Shibata
Hironobu Shibata
MAMasahiro Abe
Masahiro Abe
We retrospectively analyzed multiple myeloma (MM) patients who underwent autologous stem cell transplantation (ASCT) without maintenance therapy to assess the impact of recovery of normal immunoglobulin (Ig) on clinical outcomes. The recovery of polyclonal Ig was defined as normalization of all values of serum IgG, IgA, and IgM 1 year after ASCT. Among 50 patients, 26 patients showed polyclonal Ig recovery; 14 patients were in ≥complete response (CR) and 12 remained in non-CR after ASCT. The patients with Ig recovery exhibited a significantly better progression-free survival (PFS, median, 46.8 vs. 26.7 months, p = 0.0071) and overall survival (OS, median, not reached vs. 65.3 months, p < 0.00001) compared with those without Ig recovery. The survival benefits of Ig recovery were similarly observed in ≥CR patients (median OS, not reached vs. 80.5 months, p = 0.061) and non-CR patients (median OS, not reached vs. 53.2 months, p = 0.00016). Multivariate analysis revealed that non-CR and not all Ig recovery were independent prognostic factors for PFS (HR, 4.284, 95%CI (1.868–9.826), p = 0.00059; and HR, 2.804, 95%CI (1.334–5.896), p = 0.0065, respectively) and also for OS (HR, 8.245, 95%CI (1.528–44.47), p = 0.014; and HR, 36.55, 95%CI (3.942–338.8), p = 0.0015, respectively). Therefore, in addition to the depth of response, the recovery of polyclonal Ig after ASCT is a useful indicator especially for long-term outcome and might be considered to prevent overtreatment with maintenance therapy in transplanted patients with MM.

11 March 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
HMHirokazu Miki
Hirokazu Miki
SNShingen Nakamura
Shingen Nakamura
MOMasahiro Oura
Masahiro Oura
HHHirofumi Hamano
Hirofumi Hamano
KIKenji Ikuta
Kenji Ikuta
MAMasahiro Abe
Masahiro Abe
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

1 June 2017 in Nutrition Research
Verified
Journal Article
Closed access
HMHirokazu Miki
Hirokazu Miki
KTKatsuji Tokuhara
Katsuji Tokuhara
MOMasaharu Oishi
Masaharu Oishi
YTYoshito Tanaka
Yoshito Tanaka
RNRichi Nakatake
Richi Nakatake
MKMasanori Kon
Masanori Kon

27 October 2025 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
RSRyohei Sumitani
Ryohei Sumitani
HMHirokazu Miki
Hirokazu Miki
SNShingen Nakamura
Shingen Nakamura
MNMasafumi Nakamura
Masafumi Nakamura
THTaiki Hori
Taiki Hori
KMKen-Ichi Matsuoka
Ken-Ichi Matsuoka

Verified
Journal Article
Open access
PDF file
YKYousuke Kaneko
Yousuke Kaneko
YKYUTAKA KAWANO
YUTAKA KAWANO
SKSaki Kawata
Saki Kawata
KMKensuke Mori
Kensuke Mori
MHMinae Hosoki
Minae Hosoki
Ken-ichi AiharaKen-ichi Aihara
Ken-ichi Aihara
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) causes progressive liver fibrosis. Although erythrocyte mean corpuscular volume (MCV) has been shown to have a positive correlation with all-cause mortality, the association between MCV and the development of MASLD has not been fully elucidated. Here, we examined the clinical significance of the association between MCV and MASLD. Methods: A cross-sectional study was carried out in 1009 Japanese individuals (including 186 individuals aged < 60 years and 823 individuals aged ≥ 60 years) with metabolic disorders. The relationships between MCV and noninvasive clinical markers of liver fibrosis, including fibrosis-4 (FIB-4) index, aspartate aminotransferase-to-platelet ratio index (APRI), and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), were statistically evaluated. Results: Using multiple and logistic regression analyses in overall subjects, it was found that MCV was positively and independently associated with the values of FIB-4 index, APRI, NFS, and the prevalence of liver fibrosis defined by each index. However, the associations between the MCV value and MASLD indices were found to be positive in subjects aged ≥ 60 years but not in those aged < 60 years. Conclusions: MCV might be a simple and useful biomarker for the development of MASLD in the elderly.